Latest news with #Aspira
Associated Press
3 days ago
- Business
- Associated Press
Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health
AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 11, 2025 / Aspira Women's Health Inc., ('Aspira') (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet needs in women's health. Aspira was originally awarded a $10 Million award through ARPA-H's Sprint for Women's Health to support the development of Aspira's ENDOinform test, a non-invasive blood draw-based multi-omics test utilizing protein and microRNA biomarkers, along with patient-specific data, to fuel a powerful, AI-powered algorithm to aid in the diagnosis of endometriosis in patients with symptoms of the disease. This test, leveraging technology and expertise originally developed by Aspira for ovarian cancer risk assessment diagnostics, promises the potential to non-invasively confirm presence of suspected endometriosis in patients, enabling physicians to identify patients who may benefit from endometriosis-controlling therapeutics currently available. The original ARPA-H contract was announced on October 24, 2024, and reflected $10 million divided into eight payments. The first two of those milestone payments, for $2 million and $1.5 million, were received on November 29, 2024, and March 28, 2025, respectively, for a total of $ 3.5 million from the ARPA-H program. On June 9, 2025, Aspira received notice from ARPA-H that ARPA-H and the assigned managing contractor, VentureWell, have determined that Aspira had not met the specifications of Milestone 3, and have therefore elected to terminate the ENDOinform development program contract. Aspira's CEO, Mike Buhle, commented, 'While we are certainly disappointed in ARPA-H's termination notice, we are highly confident that our team fully achieved all specifications requirements in the Milestone 3 scope of work provisions. We achieved these requirements in early May and are well underway in achieving Milestone 4 targeted specifications. We are confident in our quality of work, and even more so in our understanding of the technical requirements to complete the ENDOinform program.' Buhle further commented, 'Our R&D team has been excited about the progress we have made, as well as the early indications of our potential success with the ENDOinform program overall. We plan to continue development of this critical women's health program with the help and support of our shareholders, our research & collaboration partners, and the ongoing dedication of our highly talented and missional teammates. ENDOinform promises a dramatic improvement in health outcomes and quality of life for millions of women suffering from endometriosis, both in the U.S. and abroad. The program remains targeted for 2026 completion goals. We look forward to continuing our development work to completion. In fact, compliance with the ARPA-H program involved significant time investment for our R&D team, and this may well offer us a material acceleration in the pace of achieving our goals.' About Aspira Women's Health Inc. Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity. Forward-Looking Statements This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as 'designed to,' 'expect,' 'plan,' 'anticipate,' 'could,' 'may,' 'intend,' 'will,' 'continue,' 'future,' and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as 'Risk Factors' in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Investor Relations Contact: [email protected] SOURCE: Aspira Women's Health press release
Yahoo
4 days ago
- Business
- Yahoo
ShiftKey Promotes Seth Rosenberg to President and Chief Operating Officer
The Promotion Comes as ShiftKey Continues to Focus on Operational Execution to Drive Growth DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- ShiftKey, a leading technology marketplace revolutionizing workforce access in healthcare and beyond, is pleased to announce the promotion of Seth Rosenberg to President and Chief Operating Officer. In this expanded role, Rosenberg will lead operational execution and drive key company-wide initiatives in alignment with ShiftKey's strategic vision, as the company continues its rapid growth and expansion into new markets. Rosenberg joined ShiftKey in 2021 as Chief Operating Officer, bringing over three decades of leadership experience, with a focus on marketplaces and SaaS in public and private equity-backed businesses. Prior to ShiftKey, he served as President at Aspira (Vista Equity Partners) and ReserveAmerica (IAC), and held senior executive roles at Camping World Holdings and Equity LifeStyle Properties. 'Seth has been instrumental in scaling our operations and driving innovation across the organization,' said Mike Vitek, CEO of ShiftKey. 'His deep expertise in operational excellence and data-driven leadership has helped position ShiftKey as the leading marketplace for licensed professionals in healthcare and beyond.' As President and COO, Rosenberg will continue to lead day-to-day operations across ShiftKey while driving critical initiatives that will benefit professional and facility marketplace users. His new role is vital as ShiftKey accelerates growth while strengthening its relationships with healthcare facilities and licensed professionals nationwide. This promotion reflects the company's commitment to building a resilient, technology-driven workforce marketplace that empowers professionals to work on their own terms. 'I'm honored to take on this expanded role at such a pivotal time for ShiftKey,' said Rosenberg. 'We're not only addressing critical workforce shortages in healthcare, but also redefining how professionals and organizations connect through technology. I look forward to continuing our mission of transforming access and integrity in the workplace.' About ShiftKey ShiftKey is a technology company committed to transforming healthcare by leveraging data and a marketplace approach to connect independent licensed professionals with facilities with open workforce needs. ShiftKey is playing a vital role in advancing empowered work, stability and solutions for professionals, facilities and the people and communities they serve. With 10,000 healthcare facilities and hundreds of thousands of independent licensed professionals on the platform, ShiftKey is the market leader in strategic workforce solutions, driving a more sustainable, inclusive and profitable workforce economy for the future. For more information about ShiftKey, visit Media Contactpress@
CBC
21-03-2025
- Business
- CBC
Manitoba government boots Tesla from EV rebate program as part of budget's 'elbows up' commitment
Social Sharing The Manitoba government is fighting back in the ongoing trade war with the United States by ending its provincial parks pass contract with a Texas-based company and kicking electric vehicles made by Elon Musk's company Tesla out of its rebate program. Those moves were part of Thursday's $25.9-billion provincial budget, in which the NDP government also pledged an additional $500,000 to its export support program to help Manitoba businesses diversify their sales beyond the United States. The changes are part of "Trump-proofing our economy," said Finance Minister Adrien Sala, who announced in his budget speech that a provincial rebate will no longer be available for people who purchase a Tesla or any electric vehicles manufactured in China. "It's part of our government's commitment to be elbows up," Sala told reporters during a budget briefing Thursday. "[U.S. President] Donald Trump is creating a historic threat to our economy." Last week, Trump hit Canada with 25 per cent tariffs on steel and aluminum. He has said he plans to implement additional levies on April 2. The Manitoba budget announced Thursday also included a worst-case scenario plan the province can implement if the tariffs continue, which included hundreds of millions of dollars of additional money to support the agriculture sector and to help businesses, among other measures. Budget targets Tesla and U.S. companies in midst of trade war 2 hours ago Duration 2:01 The threat of tariffs loomed over today's budget speech. So much so that it contains 'a contingency tariff budget.' It projects a $600M revenue shortfall if the U.S. goes ahead with its tariff threats. And hundreds of millions of additional spending to support people and businesses affected. As part of its response, Manitoba won't continue its contract with Aspira, a Texas-based firm that was contracted in 2020 to sell passes online for Manitoba provincial parks. That contract is set to end in April and won't be renewed, the government said Thursday. While it searches for a Canadian vendor, the province will make entry to all provincial parks free this year, beginning April 1, which it estimates will mean forfeiting almost $3 million in revenue. According to the budget, over $5 million has gone to the Texas firm since it began administering the park passes. Meanwhile, while the government is pledging $14.8 million to continue its electric vehicle rebate program this year, Teslas and Chinese EVs will be excluded. Manitobans can currently get a $2,500 rebate on the purchase of a used EV or plug-in hybrid, and $4,000 for a new vehicle. As of January, the province had already paid out almost $10 million in rebate s since the program was introduced last July. To be eligible, vehicles must be purchased or leased from Manitoba dealerships, with a maximum manufacturer's price of $70,000. Currently, there are six Tesla models that are eligible for the rebate. None of the vehicles on the province's current list are from Chinese manufacturers. The province hasn't said when the change to the program will take effect. The retaliation against the car company owned by Musk — a close ally of Trump who also heads up the newly created Department of Government Efficiency — follows similar moves in other provinces. In Ontario, Toronto city council has approved a change that temporarily makes newly manufactured Teslas ineligible for grant funding from the city's zero emission vehicle for hire program. And B.C. Hydro announced last week that it is excluding Tesla products from its electric vehicle charger rebate program in response to U.S. tariffs. 'Government is doing the right thing': Chamber CEO But University of Winnipeg economist Philippe Cyrenne questioned the wisdom of targeting Tesla and China by excluding their vehicles from the provincial EV rebate. Politicizing the response to tariffs "usually doesn't work out well," he said. "It's not clear why Manitoba is following suit" with Democrats in the U.S. on the pushback against Musk, he told CBC Thursday. "Six months ago we were celebrating people who bought a Tesla," Cyrenne said, but now, they have become "persona non grata." Tesla did not immediately respond to a request for comment. Lauren Stone, the finance critic for the Opposition Progressive Conservatives, said she supports buying Canadian, but thinks the government shouldn't control what people purchase. "I am not a fan of the government interfering in Manitobans' purchasing decisions," she said. "I think we should be encouraging local and expanding our export markets, but that should be up to Manitobans and their pocketbooks." Winnipeg Chamber of Commerce CEO Loren Remillard said the move against Chinese EVs is appropriate, given a 100 per cent levy on Canadian canola oil and meal, plus a 25 per cent duty on seafood and pork enacted by China this week. "We are in a global trade dispute right now, and I think it behooves Manitoba and all governments across Canada to make sure we are Canada-first," he said.
Associated Press
11-03-2025
- Business
- Associated Press
Aspira Women's Health Announces Closing of $1.37 Million Private Placement of Convertible Notes
AUSTIN, TX / ACCESS Newswire / March 11, 2025 / Aspira Women's Health Inc. ('Aspira' or the 'Company') (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purchase agreement dated March 6, 2025, pursuant to which the Company has sold and issued an aggregate principal amount of $1.37 million in the form of Senior Secured Convertible Promissory Notes due March 6, 2030 (the 'Convertible Notes') in a private placement (the 'Private Placement') with existing and new accredited investors. The Convertible Notes will be a senior, secured obligation of the Company and interest will accrue and be payable quarterly in kind at the applicable federal rate (currently 3.34%). The Convertible Notes will mature on March 6, 2030 (the 'Maturity Date'), unless earlier converted in accordance with the terms of the Convertible Notes. The Convertible Notes will be convertible into units consisting of one share of common stock and 2.25 warrants at the option of the holder at any time prior to the Maturity Date. The initial conversion price is $0.25 per unit (the 'Conversion Price'). The warrants are exercisable into common stock for five years after issuance at $0.50 per share. The investor may elect to exercise the warrants from the 6 month anniversary of the date of issuance until the first 24 months after issuance, at $0.25 per share. The warrants shall not be publicly tradeable. In addition, the Company shall have the option to convert the Convertible Notes into units at the Conversion Price if the sum of the gross proceeds from the sale of the Convertible Notes and the gross proceeds from the sale of any shares of common stock and warrants by the Company subsequent to the Private Placement equals or exceeds $4 million. Net proceeds from the offering will be used to support Aspira's ongoing commercial activities as well as general corporate purposes and working capital. In addition, the Company granted the purchasers of the Convertible Notes certain customary registration rights with respect to the shares of common stock and shares of common stock underlying the warrants issuable upon conversion of the Convertible Notes. 'We are very pleased to announce this important capital infusion,' said Mike Buhle, Chief Executive Officer at Aspira. 'We greatly appreciate this strong demonstration of support and confidence shown by these investors. These shareholders are well apprised of the current growth opportunities and near-term catalysts for Aspira, and their continued financial support has been key to our ability to successfully pursue our business objectives for 2025 and beyond.' The securities offered and sold by the Company in the Private Placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the 'SEC') or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities will not be registered under the Securities Act or any state securities laws when issued at the closing of the private placement, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws. About Aspira Women's Health Inc. Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-enabled tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the more than 1.2 million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Our in-development test pipeline will expand our ovarian cancer portfolio and address the need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests and expand the indicated population to screen women with a family history of ovarian cancer or a germline mutation. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying endometriosis independent of disease location or severity. Forward-Looking Statements This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as 'designed to,' 'expect,' 'plan,' 'anticipate,' 'could,' 'may,' 'intend,' 'will,' 'continue,' 'future,' and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as 'Risk Factors' in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
